Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

New gene therapy treats liver disorder in growing children

Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...

High folic acid in pregnancy could cause early bleeding

Women taking at least 800 micrograms of folic acid daily were more likely to report spotting and...

Genetics shape our personality and life outcomes more than we thought

Scientists have identified >1200 genetic variants associated with personality traits,...

Content from other channels on our network

PolarBlue to make clean energy in Tasmania

ARM Hub and Quantum Australia offering internships

HIMA Australia opens new regional head office in Perth

Australian manufacturing exports grow, reversing decades long trend

Remote telemetry for Tasmanian irrigation

Engineering sustainability from the ground up at Selfs Point STP

Complex solar installation for Adelaide wine venue

Australia's data centre plans can become a blueprint for the world

German company installs 'record' wind turbine with 199 m hub height

SEW projects to deliver six billion litres of recycled water annually

The cost of not cleaning: how to reduce infections and save money

WA's women's, newborn and children's model remains a "major missed opportunity", doctors say

The healthcare dog must wag the AI tail

Fear of cancer recurrence clinical pathway